Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) will present at the Benzinga Global Small Cap Conference on October 28, 2021. CEO John S. Kovach, M.D., will discuss the lead clinical compound, LB-100, a PP2A inhibitor, and its collaboration with the Netherlands Cancer Institute and Oncode Institute. This partnership aims to identify effective drug combinations and new targets for LB-100 in cancer treatment. Pre-clinical studies led by Professor René Bernards will utilize genome-wide functional genetic techniques to enhance treatment efficacy.
- Collaboration with Netherlands Cancer Institute and Oncode Institute to identify effective drug combinations.
- Pre-clinical studies led by renowned Professor René Bernards focusing on drug efficacy.
- None.
Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100
PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the Benzinga Global Small Cap Conference being held virtually October 27-28, 2021.
Event and Registration: Benzinga Global Small Cap Conference
Presentation Date: Thursday, October 28, 2021
Presentation Time: 11:55 a.m. ET
Lixte Founder and CEO John S. Kovach, M.D. will deliver a summary of the main features of its lead clinical compound, the PP2A inhibitor LB-100, and an overview of the Company’s collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to identify the most promising drug combinations for LB-100 for cancer treatment. The pre-clinical studies are directed by Professor René Bernards (NKI), a leader in using genome wide functional genetic techniques to identify effective drug combinations, new drug targets, and mechanisms of resistance to cancer drugs.
Commenting on the collaboration, Dr. Kovach recently stated, “We are extremely pleased to have the opportunity to collaborate with Professor Bernards and his excellent group. There are many pre-clinical studies demonstrating the ability of our lead compound, LB-100, an inhibitor of protein phosphatase 2A, to potentiate the activity of different cytotoxic drugs. Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound. A targeted approach to cancer treatment has been a long-standing research goal. Prof. Bernards’ approach makes it possible to select among a multitude of compounds those most likely to be effective when combined with a second drug and/or in cancers with a particular molecular abnormality. The possibility of identifying which drug in combination with LB-100 and in which type of tumor is most likely to be beneficial is a very exciting prospect.”
About Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the “on” switches because the “off” switches, especially the master “off” switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com
Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.
Lixte Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
FAQ
What is Lixte Biotechnology Holdings' presentation at the Benzinga Global Small Cap Conference about?
What is LB-100 and its significance in cancer treatment?
When will Lixte present at the Benzinga Global Small Cap Conference?
Who is leading the pre-clinical studies for LB-100?
What techniques are being used in the pre-clinical studies for LB-100?
